Abdulazeez Salawu, Ben X Wang, Ming Han, Caryn Geady, Alya Heirali, Hal K Berman, Thomas D Pfister, Alberto Hernando-Calvo, Esmail Mutahar Al-Ezzi, Lee-Anne Stayner, Abha A Gupta, Olubukola Ayodele, Bernard Lam, Aaron R Hansen, Anna Spreafico, Philippe L Bedard, Marcus O Butler, Lisa Avery, Bryan Coburn, Benjamin Haibe-Kains, Lillian L Siu, Albiruni R Abdul Razak
PURPOSE: Non-inflamed (cold) tumors such as leiomyosarcoma (LMS) do not benefit from immune checkpoint blockade (ICB) monotherapy. Combining ICB with angiogenesis-, or poly-ADP ribose polymerase (PARP) inhibitors may increase tumor immunogenicity by altering the immune cell composition of the tumor microenvironment (TME). The DAPPER phase II study evaluated the safety, immunologic, and clinical activity of ICB-based combinations in pre-treated LMS patients. PATIENTS AND METHODS: Patients were randomized to receive durvalumab 1500mg IV q4w with either Olaparib 300mg bid PO (Arm A) or Cediranib 20mg qd PO on 5 days/week (Arm B) until unacceptable toxicity or disease progression...
August 11, 2023: Clinical Cancer Research